Prosight Management, LP Ac Immune Sa Transaction History

Prosight Management, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$5.32 - $8.96 $47,571 - $80,120	-8,942 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$4.47 - $5.58 $4.09 Million - $5.1 Million	-914,175 Reduced 99.03%	8,942 $46,000
Q3 2020 Nov 13, 2020	SELL	$4.78 - $9.06 $1.21 Million - $2.3 Million	-253,684 Reduced 21.56%	923,117 $4.51 Million
Q2 2020 Aug 14, 2020	BUY	$6.57 - $8.3 $775,943 - $980,263	118,104 Added 11.16%	1,176,801 $7.92 Million
Q1 2020 May 15, 2020	SELL	$4.24 - $9.89 $780,779 - $1.82 Million	-184,146 Reduced 14.82%	1,058,697 $7.32 Million
Q4 2019 Feb 14, 2020	SELL	$4.56 - $8.78 $25,581 - $49,255	-5,610 Reduced 0.45%	1,242,843 $10.6 Million
Q3 2019 Nov 14, 2019	BUY	$4.8 - $5.89 $3.29 Million - $4.03 Million	684,553 Added 121.4%	1,248,453 $6.18 Million
Q2 2019 Aug 14, 2019	SELL	$4.72 - $5.88 $692,145 - $862,249	-146,641 Reduced 20.64%	563,900 $3.13 Million
Q1 2019 May 15, 2019	BUY	$3.65 - $11.68 $2.59 Million - $8.3 Million	710,541 New	710,541 $3.59 Million

27.9M

150K

12.4K

Ticker ACIU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,413,504
Market Cap $218M
Description
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectiv...

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

Stay updated on Prosight Management, LP with notifications on news.